Havrix 720 (Junior)

Active immunisation against Hepatitis A virus

Intramuscular Active immunisation against hepatitis A Adult: 2-dose vaccination series: 1 mL IM; separate the 2 doses by 6-12 months

Intramuscular Active immunisation against hepatitis A Child: Indicated as routine vaccination for children at least 12 months of age (ACIP guidelines) <12 months: Not indicated Routine vaccination (2-dose series): 0.5 mL IM initiated at aged 12 through 23 months; separate the 2 doses by 6-12 months Children who have received 1 dose before age 24 months, should receive a second dose 6-12 months after the first dose Catch up schedule For any person >2 yr who has not already received hepatitis A vaccine series, give 2 doses separated by 6-18 months if immunity against hepatitis A virus infection is desired Minimum interval between the 2-dose series is 6 months

Hypersensitivity. Vaccines prepared in egg cultures are contraindicated in patients with hypersensitivity reactions to egg. Severe immunodeficiency. Malignant disease being treated with chemotherapy or radiotherapy and for at least 6 mth after stopping treatment. Patients with compromised immune system such as those on high-dose systemic corticosteroids, immunosuppressants or HIV positive.

Hepatitis A antigen is prepared from formaldehyde-inactivated hepatitis A virus grown in human diploid cells. It is used for active immunisation against hepatitis A infection.

Alcohol or disinfectant used for cleaning the skin prior to inj should be allowed to evaporate completely before vaccination to prevent vaccine inactivation. Lactation: not established

>10% Injection site tenderness (3-56%), erythema (1-22%), warmth (1-17%), swelling (9-11%),Irritability (11-36%),Anorexia (1-19%),Drowsiness (15-17%),Headache (1-16%),Fever > 100.4 F (9-11%) 1-10% URI (1-10%),Otitis media (8%),Rhinorrhea (6%),Diarrhea (1-6%),Cough (1-5%),Rash (1-5%),Weakness/fatigue (4%),Vomiting (1-4%),Fever > 102 F (3%),Crying (2%) <1% Hematoma,Incr. CPK,Photophobia,Vertigo Potentially Fatal: Anaphylaxis.

Reduced response to vaccination when used concurrently with immunosuppressants such as corticosteroids or antineoplastics.